<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00437216</url>
  </required_header>
  <id_info>
    <org_study_id>US10029</org_study_id>
    <nct_id>NCT00437216</nct_id>
  </id_info>
  <brief_title>Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis</brief_title>
  <official_title>Phase 4 Open-Label Multicenter Community-Based 4-Wk Trial to Assess Efficacy, Tolerance to Tx &amp; Patient Satisfaction w/ CLOBEX® Spray When Used as Mono- or Add-on Therapy to Existing Systemic/Topical Agents for Tx of Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma Laboratories, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma Laboratories, L.P.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on
      therapy to existing systemic or topical anti-psoriatic agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on
      therapy to existing systemic or topical anti-psoriatic agents, as determined by the change in
      the target plaque severity (TPS) rating between Weeks 0 and 4.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy - Change in Target Plaque Severity rating</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Self-Assessment of Quality of Life, Subject satisfaction</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Evaluation of adverse events and tolerability</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2488</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Monotherapy - Subjects who are not currently being treated with anti-psoriatic medication and start using Clobex®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Add-on therapy - Subjects who are taking some form of anti-psoriatic medication and add Clobex® treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobetasol Propionate, 0.05%</intervention_name>
    <description>Apply twice daily for 2 or 4 weeks as monotherapy</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Clobex® Spray, 0.05%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobetasol propionate, 0.05% Spray</intervention_name>
    <description>Apply twice daily for 2 or 4 weeks as add-on therapy</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Clobex® Spray, 0.05%</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Community Sample
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe plaque psoriasis between 3% and 20% of Body Surface Area (BSA) with
             a target plaque severity (TPS) of moderate to severe

          -  At least 1 target site (not on the palms or soles of the feet) with a TPS rating of
             moderate to severe and with 1 or more elevated, easily palpable, plaques having
             well-circumscribed margins, and at least 1 cm in diameter

          -  History of stable plaque psoriasis of greater than or equal to 3 months

        Exclusion Criteria:

          -  Diagnosis of guttate, generalized pustular, erythrodermic, psoriatic arthritis, or
             nail psoriasis as the sole or predominant form of psoriasis

          -  Psoriatic arthritis that was not stable or might have required a change in medication
             during the 4-week study period

          -  Plaque psoriasis requiring treatment on the face, scalp, neck, groin, and armpits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald W Gottschalk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma Laboratories, LP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DHC Dimensional HealthCare, Inc. (Clinical Research Organization)</name>
      <address>
        <city>Cedar Knolls</city>
        <state>New Jersey</state>
        <zip>76117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2007</study_first_submitted>
  <study_first_submitted_qc>February 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2007</study_first_posted>
  <last_update_submitted>March 27, 2008</last_update_submitted>
  <last_update_submitted_qc>March 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2008</last_update_posted>
  <responsible_party>
    <name_title>Ronald W. Gottschalk, MD / Medical Director</name_title>
    <organization>Galderma Laboratories, L.P.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

